Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + NALIRIFOX or GP in First-Line Metastatic Biliary Tract Cancer
NCT07831993Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in biliary tract cancer (BTC) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Objective Response Rate. Started Jan 2026; status: recruiting.
02
Drugs
sintilimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07831993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831993.